Tuberculosis screening and isoniazid preventive therapy implementation: a Brazilian experience

References

• Lincoln EM. The effect of antimicrobial therapy on the prognosis of primary tuberculosis in children. Am Rev Tuberc 1954;69(5):682-9
   PubMedGoogle Scholar
• Comstock GW, Baum C, Snider DE Jr. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis 1979;119:827-30
   PubMed Web of Science ®Google Scholar
• Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010(1):CD000171
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO Three I's Meeting Report. Intensified case finding (ICF), Isoniazid preventive therapy (IPT) and TB infection control (IC) for people living with HIV. WHO Press; Geneva, Switzerland: 2008
   Google Scholar
• van Halesma CL, Fielding KL, Chihota VN, et al. Tuberculosis outcomes and drug susceptibility in individuals exposed to Isoniazid preventive therapy in a high HIV prevalence setting. AIDS 2010;24:1051-5
   PubMedGoogle Scholar
• Samandari T, Agizew TB, Nyirenda S, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet 2011;377:1588-98
   PubMed Web of Science ®Google Scholar
• Swaminathan S, Menon PA, Gopalan N, et al. Efficacy of a 6-month vs a 36-month regimen for prevention of TB in HIV-infected persons in India: a randomized clinical trial. PLoS One 2012;7(12):e47400
   PubMedGoogle Scholar
• Pho MT, Swaminathan S, Kumarasamy N, et al. The cost-effectiveness of tuberculosis preventive therapy for HIV-infected individuals in Southern India: a trial-based analysis. PLoS One 2012;7(4):e36001
   Google Scholar
• Sterling TR, Villarino E, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011;365(23):2155-66
   PubMed Web of Science ®Google Scholar
• Martinson NA, Barnes GL, Moulton LH, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med 2011;365:11-20
   PubMed Web of Science ®Google Scholar
• Durovni B, Cavakcabte SC, Saraceni V, et al. The implementation of Isoniazid preventive therapy in HIV clinics: the experience from the TB/HIV in Rio (THRio) study. AIDS 2010;24(Suppl 5):S49-56
   PubMedGoogle Scholar
• Durovni B, Saraceni V, Moulton LH, et al. Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomized trial. Lancet Infect Dis 2013;13(10):852-8
   PubMed Web of Science ®Google Scholar
• Rangaka M, Wilkinson R, Wilkinson K, et al. Effect of tuberculin skin testing or interferon-release on the benefit of concurrent isoniazid preventive therapy with ART: subgroup analysis of a randomized controlled trial (Poster abstract 189LB). 20th Conference on Retroviruses and Opportunistic Infections; 3 – 6 March 2013; Atlanta, GA, USA
   Google Scholar
• Swaminathan S, Ramachandran R, Bhaskaran G, et al. Risk of development of tuberculosis in HIV infected patients. Int J Tuberc Lung Dis 2000;4(9):839-44
   PubMedGoogle Scholar
• Swaminathan S, Subbaraman R, Venkatesan P, et al. Tuberculin skin test results in HIV-infected patients in India: implications for latent tuberculosis treatment. Int J Tuberc Lung Dis 2008;12(2):168-73
   PubMedGoogle Scholar
• Moolphate S, Lawpoolsri S, Pungrassami P, et al. Barriers to and motivations for the implementation of a treatment programme for latent tuberculosis infection using isoniazid for people living with HIV, in upper Northern Thailand. Glob J Health Sci 2013;5(4):60-70
   Google Scholar
• Date AA, Vitoria M, Granich R, et al. Implementation of co-trimoxazole prophylaxis and isoniazid preventive therapy for people living with HIV. Bull World Health Organ 2010;2088(4):2253-019
   Google Scholar
• Lester R, Hamilton R, Charalambous S, et al. Barriers to implementation of isoniazid preventive therapy in HIV clinics: a qualitative study. AIDS 2010;24(5):S45-8
   PubMedGoogle Scholar
• Hiransuthikul N, Hiransuthikul P, Nelson KE, et al. Physician adherence to isoniazid preventive therapy guidelines for HIV-infected patients in Thailand. Southeast Asian J Trop Med Public Health 2005;36(5):1208-15
   PubMedGoogle Scholar
• Oni T, Tsekela R, Kwaza B, et al.A Recent HIV. Diagnosis Is Associated with Non-Completion of Isoniazid Preventive Therapy in an HIV-Infected Cohort in Cape Town. PLoS One 2012;7(12):e52489
   Google Scholar
• Gust DA, Mosimaneotsile B, Mathebula U, et al. Risk factors for non-adherence and loss to follow-up in a three-year clinical trial in Botswana. PLoS One 2011;6:e18435
   Google Scholar
• Churchyard G, Fielding K, Lewis J, et al. Community-wide isoniazid preventive therapy does not improve TB control among gold miners: the Thibela TB study, South Africa (Abstract 150aLB). 19th Conference on Retroviruses and Opportunistic Infections; 5 – 8 March 2012; Seattle WA, USA
   Google Scholar
• Samandari T, Agizew T, Nyirenda et al. TB incidence increase after cessation of 36 months isoniazid prophylaxis in HIV+ adults: Botswana (Abstract 147). 19th Conference on Retroviruses and Opportunistic Infections; 5 – 8 March 2012; Seattle WA, USA
   Google Scholar
• Rangaka MX, Wilkinson RJ. Isoniazid prevention of HIV-associated tuberculosis. Lancet Infect Dis 2013;13:825-6
   PubMedGoogle Scholar